Compare Talkspace, Inc. with Similar Stocks
Dashboard
1
With a growth in Net Sales of 4.08%, the company declared Very Positive results in Jun 25
- The company has declared positive results for the last 9 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 8.69 MM
- NET PROFIT(HY) At USD -0.22 MM has Grown at 88.51%
- ROCE(HY) Highest at 2.52%
2
With ROE of 2.59%, it has a fair valuation with a 4.85 Price to Book Value
3
Market Beating performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
USD 633 Million (Micro Cap)
188.00
NA
0.00%
-0.88
3.89%
5.80
Revenue and Profits:
Net Sales:
59 Million
(Quarterly Results - Sep 2025)
Net Profit:
3 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
43.17%
0%
43.17%
6 Months
12.14%
0%
12.14%
1 Year
48.66%
0%
48.66%
2 Years
220.66%
0%
220.66%
3 Years
125.58%
0%
125.58%
4 Years
-61.18%
0%
-61.18%
5 Years
0%
0%
0.0%
Talkspace, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
189.44%
EBIT Growth (5y)
-176.38%
EBIT to Interest (avg)
-19.07
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.96
Sales to Capital Employed (avg)
1.50
Tax Ratio
1.74%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
75.00%
ROCE (avg)
0
ROE (avg)
0.65%
Valuation key factors
Factor
Value
P/E Ratio
188
Industry P/E
Price to Book Value
4.85
EV to EBIT
-113.28
EV to EBITDA
-170.31
EV to Capital Employed
87.25
EV to Sales
2.27
PEG Ratio
1.51
Dividend Yield
NA
ROCE (Latest)
-77.03%
ROE (Latest)
2.59%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 35 Schemes (17.99%)
Foreign Institutions
Held by 45 Foreign Institutions (5.16%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
59.40
54.30
9.39%
Operating Profit (PBDIT) excl Other Income
2.90
-1.10
363.64%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
3.30
-0.50
760.00%
Operating Profit Margin (Excl OI)
37.00%
-33.00%
7.00%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 9.39% vs 4.02% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 760.00% vs -266.67% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
187.60
150.00
25.07%
Operating Profit (PBDIT) excl Other Income
-3.60
-22.00
83.64%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
1.10
-19.20
105.73%
Operating Profit Margin (Excl OI)
-24.00%
-154.70%
13.07%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 25.07% vs 25.42% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 105.73% vs 75.91% in Dec 2023
About Talkspace, Inc. 
Talkspace, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






